Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. If you are an NIH recipient or applicant looking for guidance, see Guide Notice NOT-OD-26-004. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

An official website of the United States government

Here's how you know

U.S. Department of Health and Human Services National Institutes of Health

Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Modulation Therapeutics

Modulation Therapeutics is a clinical-stage company dedicated to bringing novel therapeutics to the treatment of cancer patients. Its lead molecule, MTI-201, is currently in a Phase I clinical trial; another is in development, called MTI-301. The company is developing a potent and specific inhibitor of SCD1 for the treatment of hepatocellular cancer and fatty liver disease (NASH). These indications demonstrate increased incidence worldwide, and novel treatments are required to improve patient outcomes.

Company Ownership: Woman Owned

Contact Name:

Lori Hazlehurst

Contact Email:

[email protected]

Website: https://www.modulationtherapeutics.com/

City, State – Congressional District: Morgantown,

–

Technology: Drug

Funding: Cancer (NCI)

NIH Projects: NIH RePorter for Modulation Therapeutics

Sponsored Event(s): MedCity INVEST 2024 | 2024